Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease

Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A.E., Biggs, C.S. and Whitton, P.S. 2008. Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease. Journal of Neuroinflammation. 5 (1), p. 19.

TitleGlucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease
AuthorsHarkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A.E., Biggs, C.S. and Whitton, P.S.
Abstract

Abstract (provisional). Background: It has recently become apparent that neuroinflammation may play a significant role in Parkinson's disease (PD). This is also the case in animal paradigms of the disease. The potential neuroprotective action of the glucagon-like peptide 1 receptor (GLP-1R) agonist exendin-4 (EX-4), which is protective against cytokine mediated apoptosis and may stimulate neurogenesis, was investigated In paradigms of PD.

Methods: Two rodent 'models' of PD, 6-hydroxydopamine (6-OHDA) and lipopolysaccaride (LPS), were used to test the effects of EX-4. Rats were then investigated in vivo and ex vivo with a wide range of behavioural, neurochemical and histological tests to measure integrity of the nigrostriatal system.

Results: EX-4 (0.1 and 0.5ug/kg) was given seven days after intracerebral toxin injection. Seven days later circling behaviour was measured following apomorphine challenge. Circling was significantly lower in rats given EX-4 at both doses compared to animals given 6-OHDA/LPS and vehicle. Consistent with these observations, striatal tissue DA concentrations were markedly higher in 6-OHDA/LPS + EX-4 treated rats versus 6-OHDA/LPS + vehicle groups, whilst assay of L-DOPA production by tyrosine hydroxylase was greatly reduced in the striata of 6-OHDA/LPS + vehicle rats, but this was not the case in rats co-administered EX-4. Furthermore nigral TH staining recorded in 6-OHDA/LPS + vehicle treated animals was markedly lower than in sham-operated or EX-4 treated rats. Finally, EX-4 clearly reversed the loss of extracellular DA in the striata of toxin lesioned freely moving rats.

Conclusions: The apparent ability of EX-4 to arrest progression of, or even reverse nigral lesions once established, suggests that pharmacological manipulation of the GLP-1 receptor system could have substantial therapeutic utility in PD. Critically, in contrast to other peptide agents that have been demonstrated to possess neuroprotective properties in pre-clinical models of PD, EX-4 is in current clinical use in the management of type-II diabetes and freely crosses the blood brain barrier; hence, assessment of the clinical efficacy of EX-4 in patients with PD could be pursued without delay.

JournalJournal of Neuroinflammation
Journal citation5 (1), p. 19
ISSN1742-2094
Year21 May 2008
PublisherPubMed Central
Digital Object Identifier (DOI)doi:10.1186/1742-2094-5-19
Publication dates
Published21 May 2008

Related outputs

Quin-C1: a selective Fpr2 agonist that shifts microglial phenotype following LPS and Aβ1-42 exposure
Wickstead, E., Getting, S.J., Biggs, C.S. and McArthur, S. 2018. Quin-C1: a selective Fpr2 agonist that shifts microglial phenotype following LPS and Aβ1-42 exposure. Alzheimer's Research UK Conference. London 20 - 22 Mar 2018

Reversal of β-amyloid induced microglial activation by an agonist of Fpr2
Wickstead, E., Getting, S.J., Biggs, C.S. and McArthur, S. 2017. Reversal of β-amyloid induced microglial activation by an agonist of Fpr2. British Pharmacological Society: Pharmacology 2017. London 11 - 14 Dec 2017

Activation of the pro-resolving receptor Fpr2 attenuates inflammatory microglial activation
Wickstead, E., Getting, S.J., Biggs, C.S. and McArthur, S. 2017. Activation of the pro-resolving receptor Fpr2 attenuates inflammatory microglial activation. BNA Festival of Neuroscience. Birmingham 10 - 14 Apr 2017 Sage.

Fpr2 and neuroinflammation: selective agonists with synergistic anti-oxidative and pro-resolving effects
Wickstead, E., Getting, S.J., Biggs, C.S. and McArthur, S. 2017. Fpr2 and neuroinflammation: selective agonists with synergistic anti-oxidative and pro-resolving effects. World Congress on Inflammation. London 08 - 13 Jul 2017

Urocortin, a CRF-like peptide, restores key indicators of damage in the substantia nigra in a neuroinflammatory model of Parkinson's disease
Abuirmeileh, A., Harkavyi, A., Lever, R., Biggs, C.S. and Whitton, P.S. 2007. Urocortin, a CRF-like peptide, restores key indicators of damage in the substantia nigra in a neuroinflammatory model of Parkinson's disease. Journal of Neuroinflammation. 4, p. 19.

The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease
Abuirmeileh, A., Lever, R., Kingsbury, A.E., Lees, A.J., Locke, I.C., Knight, R.A., Chowdrey, H.S., Biggs, C.S. and Whitton, P.S. 2007. The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease. European Journal of Neuroscience. 26 (2), pp. 417-423.

Evidence for a neuroprotective role of the CRH-like peptide, urocortin, in the 6-hydroxydopamine treated rat
Biggs, C.S., Locke, I.C., Knight, R.A., Chowdrey, H.S. and Whitton, P.S. 2005. Evidence for a neuroprotective role of the CRH-like peptide, urocortin, in the 6-hydroxydopamine treated rat. 18th National Meeting of the British Neuroscience Association. Brighton, UK 03-06 Apr 2005

Urocortin attenuates key indicators of nigrostriatal pathway destruction in a rat hemiparkinsonian model
Biggs, C.S., Abuirmeileh, A., Locke, I.C., Knight, R.A., Chowdrey, H.S. and Whitton, P.S. 2005. Urocortin attenuates key indicators of nigrostriatal pathway destruction in a rat hemiparkinsonian model. Proceedings of the British Pharmacological Society. 3 (4).

Biphasic modulation of GABA release by nitric oxide in the hippocampus of freely moving rats in vivo
Getting, S.J., Segieth, J., Ahmad, S., Biggs, C.S. and Whitton, P.S. 1996. Biphasic modulation of GABA release by nitric oxide in the hippocampus of freely moving rats in vivo. Brain Research. 717 (1-2), pp. 196-199.

Nitric oxide regulates excitatory amino acid release in a biphasic manner in freely moving rats
Segieth, J., Getting, S.J., Biggs, C.S. and Whitton, P.S. 1995. Nitric oxide regulates excitatory amino acid release in a biphasic manner in freely moving rats. Neuroscience Letters. 200 (2), pp. 101-104.

Permalink - https://westminsterresearch.westminster.ac.uk/item/91273/glucagon-like-peptide-1-receptor-stimulation-by-exendin-4-reverses-key-deficits-in-distinct-rodent-models-of-parkinson-s-disease


Share this
Tweet
Email